Literature DB >> 2464605

Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells.

M B Meyers1, W P Shen, B A Spengler, V Ciccarone, J P O'Brien, D B Donner, M E Furth, J L Biedler.   

Abstract

Multidrug-resistant human neuroblastoma cell lines obtained by selection with vincristine or actinomycin D from two independent clonal lines, SH-SY5Y and MC-IXC, have 3- to 30-fold more cell surface epidermal growth factor (EGF) receptors than the drug-sensitive parental cells as indicated by EGF binding assays and immunoprecipitation, affinity-labeling, and phosphorylation studies. Reversion to drug sensitivity in one line was accompanied by a return to the parental level of EGF receptor. SH-EP cells, a clone derived from the same neuroblastoma cell line as SH-SY5Y but which displays melanocyte rather than neuronal lineage markers, also express significantly more EGF receptor than SH-SY5Y cells. By nucleic acid hybridization analysis with a molecularly cloned probe, increased receptor level in multidrug-resistant cells was shown to be the result of higher levels of EGF receptor mRNA in drug-resistant than in drug-sensitive cells. The increased steady state amount of specific RNA did not result from amplification of receptor-encoding genes. A small difference was observed in the electrophoretic mobility under denaturing conditions of EGF receptor immunoprecipitated from drug-resistant and drug-sensitive cells. Quantitative and qualitative modulation of the EGF receptor might reflect alterations in the transformation and/or differentiation phenotype of the resistant cells or might result from unknown selective pressures associated with the development of multidrug resistance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464605     DOI: 10.1002/jcb.240380203

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

1.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  Src kinase family inhibitor PP2 induces aggregation and detachment of neuroblastoma cells and inhibits cell growth in a PI3 kinase/Akt pathway-independent manner.

Authors:  Tomoro Hishiki; Takeshi Saito; Yoshiharu Sato; Tetsuya Mitsunaga; Elena Terui; Gen Matsuura; Eriko Saito; Ryohei Shibata; Naoko Mise; Yukiko Yokoyama; Hideo Yoshida
Journal:  Pediatr Surg Int       Date:  2011-02       Impact factor: 1.827

3.  Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.

Authors:  H Depenbrock; A Shirvani; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 4.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

5.  EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.

Authors:  Srilatha Nalluri; Susan K Peirce; Rachel Tanos; Haneen A Abdella; Dipan Karmali; Michael D Hogarty; Kelly C Goldsmith
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 6.  Cell-signaling targets for antitumour drug development.

Authors:  V G Brunton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

Authors:  R D Christen; D K Hom; D C Porter; P A Andrews; C L MacLeod; L Hafstrom; S B Howell
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

8.  UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Authors:  Peter E Zage; Natalie Sirisaengtaksin; Yin Liu; Monica Gireud; Brandon S Brown; Shana Palla; Kristen N Richards; Dennis P M Hughes; Andrew J Bean
Journal:  Cancer       Date:  2012-09-18       Impact factor: 6.860

Review 9.  Antibody-directed therapy of multidrug-resistant tumor cells.

Authors:  T Efferth; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 10.  Reverse transformation of multidrug-resistant cells.

Authors:  J L Biedler; B A Spengler
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.